Multiple Sclerosis, Relapsing-Remitting — Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One
Citation(s)
A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Treatment-Naïve Patients With Relapsing-Remitting Multiple Sclerosis